News
GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...
24/7 Wall St. on MSN1d
Eli Lilly Ranks Among Top Large-Cap Performers as GLP-1 Drug Sales Exceed Billions
Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.
At a time when shedding pounds may be just a shot away, WeightWatchers is returning to its roots and its community to chart a ...
Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...
Fact checked by Nick Blackmer With anti-obesity medications like Ozempic, Wegovy, and Zepbound exploding in popularity in ...
The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.
Everyone is allowed to have their own opinion. But it’s important for me to own my own narrative and tell my own story.” ...
As Eli Lilly and Novo Nordisk have been battling it out to gain market share of the growing GLP-1 weight loss market, one ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback